Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203885 · ClinicalTrials.gov registry record · NA
AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment
A NA study, sponsored by Harvard Medical School (HMS and HSDM).
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT07203885 is a NA study that has completed, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 10 participants.
The verdict
NCT07203885, a NA study, has completed, sponsored by Harvard Medical School (HMS and HSDM).
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will test whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Doctors usually examine bone marrow samples under a microscope to make this diagnosis, but it can be challenging and time-consuming. In this study, doctors will review bone marrow samples under three different conditions: * Unaided Review: Without AI assistance. * AI as Double-Check: AI-generated evaluation shown after the doctor makes an initial decision. * AI as First Look: AI-generated evaluation shown at the start of the review. Doctors will be randomly assigned to different orders of these three conditions. This design will allow us to compare how AI support affects diagnostic accuracy, speed, and confidence.
Interventions
- BEHAVIORAL Unaided Review First, Then AI-Assisted Review
- BEHAVIORAL AI-Assisted Review First, Then Unaided Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2025-10-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07203885
The ClinicalTrials.gov registry entry for NCT07203885 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harvard Medical School (HMS and HSDM), which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Unaided Review First, Then AI-Assisted Review is the first listed.
NCT07203885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07203885 about?
NCT07203885 is a clinical study titled "AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment". This study will test whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Doctors usually examine bone marrow samples under a microscope to make this diagnosis, but it can be challenging and time-con...
What is the current status of trial NCT07203885?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2025-09-09. Estimated completion is 2025-10-10.
What interventions are being tested in trial NCT07203885?
The interventions under investigation include: Unaided Review First, Then AI-Assisted Review (BEHAVIORAL), AI-Assisted Review First, Then Unaided Review (BEHAVIORAL).
Who is sponsoring clinical trial NCT07203885?
This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.